Neratinib (an irreversible inhibitor of HER1, HER2, and HER4) showed an overall survival rate of 12%, with a decrease in gallbladder tumor size or extrahepatic location in patients with advanced BC and HER2 mutation [53]. Here, ERBB2 is linked to gallbladder neoplasm.